Combined targeting of HER2 and VEGFR2 for effective treatment of HER2 -amplified breast cancer brain metastases
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Brain metastases are a serious obstacle in the treatment of patients with human epidermal growth factor receptor-2 ( HER2 )–amplified breast cancer. Although extracranial disease is controlled with HER2 inhibitors in the majority of patients, brain metastases often develop. Because these brain metastases do not respond to therapy, they are frequently the reason for treatment failure. We developed a mouse model of HER2 -amplified breast cancer brain metastasis using an orthotopic xenograft of BT474 cells. As seen in patients, the HER2 inhibitors trastuzumab and lapatinib controlled tumor progression in the breast but failed to contain tumor growth in the brain. We observed that the combination of a HER2 inhibitor with an anti–VEGF receptor-2 (VEGFR2) antibody significantly slows tumor growth in the brain, resulting in a striking survival benefit. This benefit appears largely due to an enhanced antiangiogenic effect: Combination therapy reduced both the total and functional microvascular density in the brain xenografts. In addition, the combination therapy led to a marked increase in necrosis of the brain lesions. Moreover, we observed even better antitumor activity after combining both trastuzumab and lapatinib with the anti-VEGFR2 antibody. This triple-drug combination prolonged the median overall survival fivefold compared with the control-treated group and twofold compared with either two-drug regimen. These findings support the clinical development of this three-drug regimen for the treatment of HER2 -amplified breast cancer brain metastases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“treatment with an antibody targeting VEGF receptor 2 (VEGFR2) increased the efficacy of HER2-targeted therapies against established brain metastases from HER2-positive breast cancer in a mouse xenograft model43”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [43]
Citations
Cites
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“not result in an increased invasive phenotype, similar to what is observed after anti-VEGF therapy in primary brain tumors, especially after tumor hypoxia (36).”
BackgroundResultSelf-citationLapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081 · cited 1×
“In patients with metastatic breast cancer, the anti-VEGF antibody bevacizumab (Genentech/Roche), in combination with paclitaxel, prolonged progression-free survival but not overall survival compared with paclitaxel alone (15).”
BackgroundAngiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Genes that mediate breast cancer metastasis to the brain
Bos, P. D., Zhang, X. H.-F., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., Minn, A. J., van de Vijver, M. J., Gerald, W. L., Foekens, J. A., et al. (2009) · Nature · doi:10.1038/nature08021 · Cited by 1,863 · cited 1×
“Although our direct brain parenchymal tumor implantation model lacks several earlier steps in the metastatic cascade (35), it allows for consistent tumor volume at treatment initiation as well as real-time evaluation of therapeutic efficacy using imaging and blood surrogate marker evaluation.”
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573 · cited 1×
“VEGF is one of the most potent angiogenic factors (14).”
BackgroundReal-time imaging reveals the single steps of brain metastasis formation.
Kienast, Y., von Baumgarten, L., Fuhrmann, M., Klinkert, W. E. F., Goldbrunner, R., Herms, J., & Winkler, F. (2010) · Nature Medicine · doi:10.1038/nm.2072 · Cited by 1,138
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 1×
“A recent study by our group confirmed better growth inhibition in primary breast tumors with the standard dose ofDC101 (40 mg/kg) compared with lower doses, owing to a superior antiangiogenic effect (37).”
BackgroundSelf-citationTumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996 · cited 1×
“Indeed, carcinoma-associated fibroblasts as well as immune cells can produce significant amounts of VEGF in breast cancer models (19, 20).”
BackgroundSelf-citationKonecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914 · cited 1×
“Although this concentration is one-third of that reached in tumors growing in the mammary fat pad, it is at least 500-fold greater than the in vitro IC50 for this cell line (25).”
BackgroundLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623 · cited 1×
“We have previously shown that trastuzumab alone can act as an antiangiogenic mixture in a leptomeningeal metastasis model of HER2-overexpressing breast cancer through a reduction in proangiogenic factors and an increase in an antiangiogenic factor (18).”
BackgroundSelf-citationThe biology of brain metastases—translation to new therapies
Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.58 · Cited by 567 · cited 1×
“Thus, alternative strategies are desperately needed to treat patients with metastatic disease (11).”
BackgroundSelf-citationBlackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6725 · Cited by 547 · cited 1×
“Furthermore, these preclinical results are supported by clinical data in both the preoperative primary and metastatic settings (30, 31).”
BackgroundSpector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497 · cited 1×
“In addition to direct signaling inhibition, another mechanism proposed for trastuzumab’s efficacy is antibody-dependent cell cytotoxicity, mediated by natural killer (NK) cells (26).”
BackgroundGarrett, J. T., Olivares, M. G., Rinehart, C., Granja-Ingram, N. D., Sánchez, V., Chakrabarty, A., Dave, B., Cook, R. S., Pao, W., McKinely, E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016140108 · Cited by 467 · cited 2×
“Another report shows incomplete inhibition of the HER2 kinase after lapatinib monotherapy, and the addition of trastuzumab better suppresses HER3 phosphorylation by blocking ligand-independent interactions between HER2 and HER3 (29).”
BackgroundLin, N. U., Carey, L. A., Liu, M. C., Younger, J., Come, S. E., Ewend, M., Harris, G. J., Bullitt, E., Van den Abbeele, A. D., Henson, J. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3588 · Cited by 456
Brain Metastases: The HER2 Paradigm
Lin, N. U., & Winer, E. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2478 · Cited by 417 · cited 1×
“A combination of factors explains this phenomenon, including the proclivity of HER2-positive tumor cells to colonize the brain and improved control of extracranial disease with the anti-HER2 monoclonal antibody trastuzumab (Genentech/Roche) enabling patients to live long enough to develop brain metastases (1, 5).”
BackgroundBrufsky, A. M., Mayer, M., Rugo, H. S., Kaufman, P. A., Tan-Chiu, E., Tripathy, D., Tudor, I. C., Wang, L. I., Brammer, M. G., Shing, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2962 · Cited by 386
Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis.
Kumar, S., Ghellal, A., Li, C., Byrne, G. J., Haboubi, N. Y., Wang, J. M., & Bundred, N. J. (1999) · PubMed · Cited by 361
Guarneri, V., Frassoldati, A., Bottini, A., Cagossi, K., Bisagni, G., Sarti, S., Ravaioli, A., Cavanna, L., Giardina, G., Musolino, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0823 · Cited by 360 · cited 1×
“Furthermore, these preclinical results are supported by clinical data in both the preoperative primary and metastatic settings (30, 31).”
BackgroundHer-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain
Palmieri, D., Bronder, J. L., Herring, J. M., Yoneda, T., Weil, R. J., Stark, A. M., Kurek, R., Vega-Valle, E., Feigenbaum, L., Halverson, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3316 · Cited by 333 · cited 1×
“A combination of factors explains this phenomenon, including the proclivity of HER2-positive tumor cells to colonize the brain and improved control of extracranial disease with the anti-HER2 monoclonal antibody trastuzumab (Genentech/Roche) enabling patients to live long enough to develop brain metastases (1, 5).”
BackgroundWitte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., & Böhlen, P. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006094117427 · Cited by 307 · cited 3×
“We also thank ImClone Systems/Eli Lilly and Company for the generous gift of DC101.”
BackgroundInfluentialA secreted luciferase for ex vivo monitoring of in vivo processes
Wurdinger, T., Badr, C., Pike, L., de Kleine, R., Weissleder, R., Breakefield, X. O., & Tannous, B. A. (2008) · Nature Methods · doi:10.1038/nmeth.1177 · Cited by 284 · cited 1×
“BT474 cells were transduced with an expression cassette encoding Gluc and CFP separated by an internal ribosomal entry site, using a lentiviral vector as previously described (24, 38).”
MethodSelf-citationXia, W., Gerard, C. M., Liu, L., Baudson, N. M., Ory, T. L., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258 · cited 1×
“One report attributes this to the marked downregulation of the protein survivin, leading to enhanced tumor cell apoptosis following the combination of the two agents (28).”
BackgroundBevacizumab Safety in Patients with Central Nervous System Metastases
Besse, B., Lasserre, S. F., Compton, P., Huang, J., Augustus, S., & Rohr, U.-P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2439 · Cited by 241 · cited 1×
“However, retrospective analysis has shown this potential risk may not be significant (17).”
BackgroundLeyland-Jones, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8481 · Cited by 233 · cited 1×
“Although systemic disease is under control in many of these patients, their associated brain metastases appear resistant to trastuzumab (2, 6, 7).”
BackgroundThe role of the organ microenvironment in brain metastasis
Fidler, I. J. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.12.009 · Cited by 217
Harmey, J. H., Dimitriadis, E., Kay, E., Redmond, H. P., & Bouchier-Hayes, D. (1998) · Annals of Surgical Oncology · doi:10.1007/bf02303785 · Cited by 192
du Manoir, J. M., Francia, G., Man, S., Mossoba, M. E., Medin, J. A., Viloria‐Petit, A., Hicklin, D. J., Emmenegger, U., & Kerbel, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1109 · Cited by 151 · cited 1×
“This hypothesis is consistent with the finding that targeting both HER2 and VEGF in orthotopic breast cancer xenografts results in better growth delay than targeting either agent alone (21, 22).”
ResultStemmler, H., Kahlert, S., Siekiera, W., Untch, M., Heinrich, B., & Heinemann, V. (2005) · The Breast · doi:10.1016/j.breast.2005.04.017 · Cited by 150 · cited 1×
“Although systemic disease is under control in many of these patients, their associated brain metastases appear resistant to trastuzumab (2, 6, 7).”
BackgroundHurvitz, S. A., Betting, D. J., Stern, H. M., Quinaux, E., Stinson, J., Seshagiri, S., Zhao, Y., Buyse, M., Mackey, J., Driga, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2294 · Cited by 115 · cited 1×
“These findings are consistent with clinical data showing a lack of association between Fcγ receptor genotypes and trastuzumab efficacy (27).”
ResultChung, E., Yamashita, H., Au, P., Tannous, B. A., Fukumura, D., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008316 · Cited by 100 · cited 3×
“BT474 cells were transduced with an expression cassette encoding Gluc and CFP separated by an internal ribosomal entry site, using a lentiviral vector as previously described (24, 38).”
MethodSelf-citationLe, X., Mao, W., Lu, C., Thornton, A., Heymach, J. V., Sood, A. K., & Bast, R. C. (2008) · Cell Cycle · doi:10.4161/cc.7.23.7212 · Cited by 65 · cited 1×
“This hypothesis is consistent with the finding that targeting both HER2 and VEGF in orthotopic breast cancer xenografts results in better growth delay than targeting either agent alone (21, 22).”
ResultPreclinical approaches to study the biology and treatment of brain metastases
Cruz‐Muñoz, W., & Kerbel, R. S. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.12.001 · Cited by 53
Martín, M., Makhson, A. N., Gligorov, J., Lichinitser, M., Lluch, A. M., Семиглазов, В. Ф., Scotto, N., Mitchell, L., & Tjulandin, S. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0344 · Cited by 52 · cited 2×
“Furthermore, the phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER2-positive locally recurrent or metastatic breast cancer showed an overall response rate of 73% (16).”
BackgroundPestalozzi, B., Holmes, E. M., Metzger, O., de, A. E., Hogge, L., Scullion, M. J., Gelber, R. D., Piccart, M. J., & Cameron, D. (2011) · Cancer Research · doi:10.1158/0008-5472.sabcs11-p4-17-01 · Cited by 3
HER2011: The Changing Face of HER2-Positive Breast Cancer
Sledge, G. W. (2011) · Clinical Breast Cancer · doi:10.3816/cbc.2011.n.001 · Cited by 2 · cited 1×
“Although systemic disease is under control in many of these patients, their associated brain metastases appear resistant to trastuzumab (2, 6, 7).”
Background
Research works printed but not linked: 4
- 10.1200/jco.2008.19.8481 · DOI · Paper page
- 10.1038/nrclinonc.2011.58 · DOI · Paper page
- 10.1038/416279b · DOI · Paper page
- 10.1038/nature10144 · DOI · Paper page
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationThe blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C. D., Ferraro, G. B., & Jain, R. K. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,792
Self-citationAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
“To this end, we combined HER2-targeted drugs (trastuzumab and lapatinib) with an anti-VEGFR2 antibody and demonstrated a significant improvement in survival of mice bearing HER2+ tumors in the brain (Kodack et al., 2012).”
Self-citationCNS Metastases in Breast Cancer: Old Challenge, New Frontiers
Lin, N. U., Amiri-Kordestani, L., Palmieri, D., Liewehr, D. J., & Steeg, P. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0790 · Cited by 1,286
“VEGF receptor-2 antibody, compared with control or antiHER2-therapy alone (75).”
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
“Our recent work using a VEGFR2-blocking antibody combined with trastuzumab and lapatinib has shown a dramatic effect in an experimental model of brain metastasis of human epidermal growth factor receptor 2–positive breast cancer (Data Supplement Fig S21).(164) This finding needs to be tested in the clinic.”
BackgroundSelf-citation
Metadata
- Authors
- Kodack, D. P., Chung, E., Yamashita, H., Incio, J., Duyverman, A. M. M. J., Song, Y., Farrar, C. T., Huang, Y., Ager, E., Kamoun, W., Goel, S., Snuderl, M., Lussiez, A., Hiddingh, L., Mahmood, S., Tannous, B. A., Eichler, A. F., Fukumura, D., Engelman, J. A., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Gwangju Institute of Science and Technology (KR)
- Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology,
- Department of Medicine,
- Athinoula A. Martinos Center for Biomedical Imaging (US)
- Department of Neurology, and
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-09-26
- Volume
- 109
- Issue
- 45
- Pages
- E3119-27
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3494882
- OpenAlex
- W2085327953
- Cited by
- 153
- References
- 38
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 16 · 2019: 10 · 2018: 11 · 2017: 14 · 2016: 8 · 2015: 17 · 2014: 12 · 2013: 16
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute on Aging (K25AG029415)
- National Cancer Institute (T32CA073479, R01CA096915, P01CA080124, R21CA155862, R01CA126642)
- Topics
- Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HER2-amplified breast cancer, brain metastases, VEGFR2, trastuzumab, lapatinib, combination therapy, antiangiogenic activity, microvessel density, tumor necrosis, BT474 xenograft, orthotopic xenograft, overall survival
- MeSH terms
- Trastuzumab, Lapatinib, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Blood Vessels, Brain Neoplasms, Breast Neoplasms, Diagnostic Imaging, Disease Models, Animal, Female, Gene Amplification, Humans, Killer Cells, Natural, Necrosis, Neovascularization, Pathologic, Quinazolines, Survival Analysis, Treatment Outcome, Cell Death, Erb-b2 Receptor Tyrosine Kinases, Xenograft Model Antitumor Assays, Receptors, Vascular Endothelial Growth Factor, Cell Proliferation, Mice, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.